Autopsy report · NCT06052852
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Ran for about 1 year 10 months before it stopped.
- 17 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Bolt Biotherapeutics, Inc.
- Sponsor type
- Industry
- Conditions
- Triple Negative Breast Cancer; Clear Cell Renal Cell Carcinoma; Ovarian Cancer; Head and Neck Cancer; Colorectal Cancer; Non-small Cell Lung Cancer
- Interventions
- BDC-3042; Cemiplimab
- Participants
- 17
- Sites
- 6
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.